Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors. Mu W, Katsoulakis E, Whelan CJ, Gage KL, et al. Br J Cancer 2021;125:229-239.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mu W, Katsoulakis E, Whelan CJ, Gage KL, et al. Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors. Br J Cancer 2021;125:229-239.
PMID: 33828255